Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Crunch Time For Bluebird’s Neurodegenerative Disorder Gene Therapy

US Filing Expected Mid-2021

Executive Summary

The EU could become the first market in which eli-cel is approved if the gene therapy for cerebral adrenoleukodystrophy this week passes muster with the European Medicines Agency.

You may also be interested in...



Yes Or No? Decisions Due On New EU Drug Applications

Myovant, Bayer and Rhythm Pharmaceuticals are among the companies that could soon learn whether the European Medicines Agency thinks their drugs are fit for approval.

Three Cell And Gene Therapies Reach Critical Review Stage In EU

A number of advanced therapies are likely to be approved in the EU this year.

Bluebird Lenti-D Data Give Gene Therapy Business Another Boost

The news comes less than a week after data partially exonerated its other gene therapy in a cancer scare announced in February.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS144328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel